Base-edited hematopoietic stem and progenitor cells therapy (NIAID)

N/A

Report date: 2025/07/29 20:00:11

Base Information

Drug NameBase-edited hematopoietic stem and progenitor cells therapy (NIAID)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Gene editing > Base editingCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy

Mechanisms of ActionCD40 ligand modulators

TargetsCD40 ligand

Therapy Area/IndicationsHyper-IgM Immunodeficiency Syndrome, Type 1

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)

China Registration ClassN/A

Develop Information

Active CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)

Inactive CompaniesN/A

Active IndicationsHyper-IgM Immunodeficiency Syndrome, Type 1

Inactive IndicationsN/A

Other Information

ATC CodeN/A